医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Premature Ejaculation – Pipeline Review, H2 2012

2012年09月26日 AM01:50
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/bkts2r/premature) has announced the addition of Global Markets Direct’s new report “Premature Ejaculation – Pipeline Review, H2 2012″ to their offering.

Global Markets Direct’s, ‘Premature Ejaculation – Pipeline Review, H2 2012′, provides an overview of the Premature Ejaculation therapeutic pipeline. This report provides information on the therapeutic development for Premature Ejaculation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Ejaculation. ‘Premature Ejaculation – Pipeline Review, H2 2012′ is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

– A snapshot of the global therapeutic scenario for Premature Ejaculation.

– A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

– Coverage of products based on various stages of development ranging from discovery till registration stages.

– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

– Coverage of the Premature Ejaculation pipeline on the basis of route of administration and molecule type.

– Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

– Key discontinued pipeline projects

Reasons to buy

– Identify and understand important and diverse types of therapeutics under development for Premature Ejaculation.

– Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

– Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

– Devise corrective measures for pipeline projects by understanding Premature Ejaculation pipeline depth and focus of Premature Ejaculation therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/bkts2r/premature

Source: Global Markets Direct

CONTACT

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作